According to the Trust for America's Health, in 2017, public health represented just 2.5% of all U.S. health spending.
Surveillance and epidemiology are key tactics in this quest, but critical gaps in our capacity have been clear since Covid-19 hit the U.S. Of greatest impact were the now well-known mistakes in novel coronavirus testing that left the government blind to its spread. This inability to trace the pandemic was exacerbated by the clinical manifestations of Covid-19.
The ability to do such testing would allow us not just to understand the biology and course of Covid-19 but also, potentially, to certify health caregivers and other workers who will not risk acquiring or transmitting the infection.
These have included work with anti-viral compounds, such as remdesivir, a compound developed by Gilead Sciences, which failed in treatments for Ebola but have shown promise with some Covid-19 patients; antimicrobials, such as the antimalarial drugs hydroxychloroquine and chloroquine, used together with the antibiotic azithromycin, which have shown mixed results in small trials; and remedies for severe Covid-19, such as the compounds sarilumab from Regeneron Pharmaceuticals and Sanofi, and toclizumab from Roche Holding.
The experience with Covid-19 is a powerful reminder of the importance of conducting excellent clinical trials that generate the proof needed to assure caretakers and patients.
Anyone who studies the Covid-19 pandemic knows that we need a vaccine, and we need one quickly.
Global collaborations for rapidly developing and producing vaccines for Covid-19 include Biogen and VIR Biotechnology, Pfizer and BioNTech, GlaxoSmithKline and Clover Health, and many others.
https://www.wsj.com/articles/preparing-for-the-next-pandemic-11585936915
Surveillance and epidemiology are key tactics in this quest, but critical gaps in our capacity have been clear since Covid-19 hit the U.S. Of greatest impact were the now well-known mistakes in novel coronavirus testing that left the government blind to its spread. This inability to trace the pandemic was exacerbated by the clinical manifestations of Covid-19.
The ability to do such testing would allow us not just to understand the biology and course of Covid-19 but also, potentially, to certify health caregivers and other workers who will not risk acquiring or transmitting the infection.
These have included work with anti-viral compounds, such as remdesivir, a compound developed by Gilead Sciences, which failed in treatments for Ebola but have shown promise with some Covid-19 patients; antimicrobials, such as the antimalarial drugs hydroxychloroquine and chloroquine, used together with the antibiotic azithromycin, which have shown mixed results in small trials; and remedies for severe Covid-19, such as the compounds sarilumab from Regeneron Pharmaceuticals and Sanofi, and toclizumab from Roche Holding.
The experience with Covid-19 is a powerful reminder of the importance of conducting excellent clinical trials that generate the proof needed to assure caretakers and patients.
Anyone who studies the Covid-19 pandemic knows that we need a vaccine, and we need one quickly.
Global collaborations for rapidly developing and producing vaccines for Covid-19 include Biogen and VIR Biotechnology, Pfizer and BioNTech, GlaxoSmithKline and Clover Health, and many others.
https://www.wsj.com/articles/preparing-for-the-next-pandemic-11585936915
No comments:
Post a Comment